Roche's Enspryng wins FDA approval for thyroid eye disease
Key highlights
- FDA approved Enspryng (satralizumab) for the treatment of thyroid eye disease (TED).
- Enspryng (satralizumab) is described as a first‑in‑class IL‑6 receptor (IL‑6R) inhibitor.
- The approval establishes Enspryng as the first and only at‑home subcutaneous treatment option for TED.
- Chugai Pharmaceutical issued a notice reporting Roche’s media release about the approval.
Announcement
Chugai Pharmaceutical reported that Roche issued a media release stating that Enspryng (satralizumab) has been approved by the U.S. Food and Drug Administration for the treatment of thyroid eye disease (TED).
Product profile
Enspryng is characterized in the release as a first‑in‑class interleukin‑6 receptor (IL‑6R) inhibitor and is presented as the first and only at‑home subcutaneous treatment option for TED.
Source
The information was circulated via Roche’s media release and referenced by Chugai Pharmaceutical in its announcement.
Source: Chugai Pharmaceutical